Switch to:
GuruFocus has detected 5 Warning Signs with Teva Pharmaceutical Industries Ltd $TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Research & Development
$2,111 Mil (TTM As of Dec. 2016)

This is the expense the company spent on research and development. Teva Pharmaceutical Industries Ltd's research and development for the three months ended in Dec. 2016 was $684 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2016 was $2,111 Mil.


Definition

This is the expense the company spent on research and development.

Teva Pharmaceutical Industries Ltd Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 was 389 (Mar. 2016 ) + 375 (Jun. 2016 ) + 663 (Sep. 2016 ) + 684 (Dec. 2016 ) = $2,111 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Teva Pharmaceutical Industries Ltd Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 5812,1888029331,0951,3561,4271,4881,5252,111

Teva Pharmaceutical Industries Ltd Quarterly Data

Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16
Research & Development 412379332386361446389375663684
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK